Dioun SM, et al. – Researchers performed a retrospective study involving women with gynecologic cancer (n = 235) who received pegylated liposomal doxorubicin (PLD) from 2006 to 2018, following IRB approval, to evaluate the need for pretreatment cardiac assessment in individuals who receive PLD. No cardiac surveillance was noted in 16 individuals in the cohort. In total, 183 and 36 of the residual individuals who underwent cardiac testing received multigated radionucleotide scans and had echocardiography, respectively. No important variation in median ejection fraction was noted in 56 individuals who had both pre- and posttreatment cardiac testing. Three acquired PLD-associated cardiac toxicity; however, only one had critical manifestations necessitating discontinuation of PLD therapy. Hence, routine cardiac testing prior to, during, or following treatment with PLD might not be needed. Moreover, for individual cases for whom the clinical doubt of PLD-related cardiac toxicity is significant, cardiac testing could be more relevant.